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Rhabdomyosarcoma (RMS), the most common cancer of connective tissues in pedi-
atrics, is often resistant to conventional therapies. One underlying mechanism of this 
resistance is the overexpression of Inhibitor of Apoptosis (IAP) proteins, leading to a 
dysfunctional cell death program within tumor cells. Smac mimetics (SM) are small 
molecules that can reactivate the cell death program by antagonizing IAP proteins and 
thereby compensating their overexpression. Here, we report that SM sensitize two 
RMS cell lines (RD and RH30) toward natural killer (NK) cell-mediated killing on the one 
hand, and increase the cytotoxic potential of NK cells on the other. The SM-induced 
sensitization of RH30 cells toward NK cell-mediated killing is significantly reduced 
through blocking tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) on NK 
cells prior to coculture. In addition, the presence of zVAD.fmk, a pancaspase inhibitor, 
rescues tumor cells from the increase in killing, indicating an apoptosis-dependent cell 
death. On the NK cell side, the presence of SM in addition to IL-2 during the ex vivo 
expansion leads to an increase in their cytotoxic activity against RH30 cells. This effect is 
mainly TNFα-dependent and partially mediated by NK cell activation, which is associated 
Abbreviations: (A/E)RMS, (alveolar/embryonal) rhabdomyosarcoma; CIK cells, cytokine-induced killer cells; CFSE, carboxy-
fluorescein succinimidyl ester; DAPI, 4’,6-diamidino-2-phenylindole; DC, dendritic cell; DLI, donor lymphocyte infusions; 
DNAM, DNAX accessory molecule; FasL, Fas ligand; FBS, fetal bovine serum; ICAM, intercellular adhesion molecule; IFN, 
interferon; KIR, killer immunoglobulin like receptor; LFA, lymphocyte function-associated antigen; MIC, MHC class I 
polypeptide-related sequence; MHC, major compatibility complex; NF-κB, nuclear factor “kappa-light-chain-enhancer” of 
activated B-cells; NK cells, natural killer cells; NKG2D, natural killer group 2, member D; PenStrep, penicillin/streptomycin; 
PVR, poliovirus receptor; RING, really interesting new gene; RPMI, Roswell Park Memorial Institute 1640; rt-PCR, real-
time polymerase chain reaction; Smac, second mitochondria-derived activator of caspases; SM, Smac mimetic; TNFα, tumor 
necrosis factor α; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; ULBP, UL16-binding protein; (X/c) IAPs, 
(X-linked/cellular) inhibitor of apoptosis proteins.
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inTrODUcTiOn
Cancer is the second leading cause of death in children after 
accidents (1). The most common type of cancer is leukemia, fol-
lowed by cancer of the brain and nervous system, and soft tissue 
sarcomas including rhabdomyosarcomas (RMS) (2). The survival 
of pediatric cancer has improved through progress in treatment 
(1, 3). However, the outcome greatly depends on the type of 
cancer. RMS ranks second to last in the 5-year survival rate, four 
out of five high-risk patients are defeated by their disease (4, 5). 
Especially the histological subgroup referred to as alveolar RMS 
(ARMS) is known for its aggressive growth, while embryonal sar-
comas (ERMS) are correlated to a slightly better outcome (3). The 
low overall survival rate is due to resistance against established 
therapy regimens comprising chemo- and radiotherapy in first 
place or relapse after initial therapy, underlining the necessity of 
new treatment approaches. Here, we address two possibilities of 
improving anticancer therapy for ARMS with one single drug: 
sensitizing tumor cells on the one hand, and activating immune 
effector cells on the other.
The essential idea of the first approach is to overcome one of 
the key features of malignant cells: the resistance to apoptosis 
(6). This resistance is frequently caused by an imbalance between 
pro- and antiapoptotic proteins, resulting in a dysfunctional 
intrinsic cell death program. Since anticancer therapies such 
as chemo- and radiotherapy function by triggering cell death 
pathways, the intrinsic defect within the cell leads to treatment 
failure, associated with tumor progression and poor survival 
(7). Proteins known to play a role in the regulation of apopto-
sis are the IAP proteins and their physiological antagonists: 
second mitochondria-derived activator of caspases (Smac). 
Overexpression of IAP proteins (8–11), as well as the reduced 
expression of Smac (12, 13) in human malignancies have been 
correlated with treatment resistance and tumor growth. This 
has led to the development of small-molecule compounds 
that antagonize IAP proteins, i.e., Smac mimetics (SM). SM 
assume the function of the endogenous Smac by neutralizing 
IAP proteins, thereby rendering cancer cells more susceptible 
to the induction of apoptosis (14). While X-linked IAP (XIAP) 
proteins directly bind and inhibit caspases (15–17), cellular IAP 
(cIAP) proteins play an important role in regulating signaling 
pathways within a cell through an intrinsic ubiquitin ligase 
activity in their C-terminal RING domain (18). One signaling 
pathway known to be regulated by cIAP proteins is the nuclear 
factor “kappa-light-chain-enhancer” of activated B-cells (NF-κB) 
pathway. The NF-κB family comprises several transcription 
factors that regulate genes that are involved in cell survival, as 
well as innate and adaptive immune response (19) such as the 
tumor necrosis factor α (TNFα), TRAIL, interferon γ (IFN-γ), 
and MHC class I (20).
Research over the last years revealed the broad field of immune 
therapy as a promising anticancer strategy (21, 22). Especially 
NK cells, immune effector cells that physiologically recognize 
and eliminate cancer cells, are of great interest for adoptive cell 
therapy. NK cells are equipped with a broad range of receptors 
on their surface, allowing the discrimination between healthy 
and malignantly transformed or virus-infected cells. Once 
activated, NK cells have different strategies to kill their targets 
such as exocytosis of secretory lysosomes containing cytolytic 
proteins (perforin, granzymes, Fas ligand) (23, 24), induction 
of apoptosis in the death receptor-bearing target cell through 
ligation with FasL or TRAIL expressed on the NK cell surface 
(25, 26), or further immune activation through the secretion of 
cytokines such as IFN-γ and TNFα (27). Considering the current 
state of knowledge and understanding, NK cell infusions can be 
referred to as safe in autologous and allogeneic settings (28, 29). 
Some antitumor effects have been shown for hematological as 
well as several solid tumors (30–32). Current limitations of NK 
cell therapy are the exhaustion of cellular cytotoxicity (33) and 
the resistance of tumor cells to the induction of apoptosis per se. 
In this work, we investigate the potential of the small-molecule 
SM BV6 to influence both effector and target cells simultaneously, 
enhancing the susceptibility of tumor cells to NK cell-mediated 
killing on the one hand and increasing the cytotoxic activity of 
NK cells on the other.
MaTerials anD MeThODs
cell culture
All work with cell lines was performed under sterile conditions, 
using sterile media, buffer, and material. Both RMS cell lines used, 
RH30 as an alveolar and RD as an embryonal RMS cell line, were 
cultured in Roswell Park Memorial Institute 1640 GlutaMAX 
medium (RPMI 1640) with 10% fetal bovine serum and 1% 
penicillin/streptomycin (PenStrep). The cells were split approxi-
mately twice a week depending on the growth rate and stored in 
an incubator at 37°C, 5% CO2, and 90% relative humidity.
This study was approved by the Ethics Committee of the 
Goethe University Frankfurt, Germany and carried out in 
accordance with the Declaration of Helsinki. All subjects gave 
written informed consent in accordance with the Declaration 
of Helsinki. NK cells were isolated out of freshly generated male 
donor buffy coats provided by the GRC-Blood Donor Service 
(DRK-Blutspendedienst) in Frankfurt, using immunomagnetic 
negative selection (EasySep Human NK Cell Enrichment Kit, 
with transcriptional upregulation of NF-κB target genes such as IκBα and RelB. Taken 
together, our findings implicate that SM represent a novel double-hit strategy, sensitizing 
tumor and activating NK cells with one single drug.
Keywords: natural killer cells, second mitochondria-derived activator of caspases mimetic, rhabdomyosarcoma, 
rh30 cells, rD cells, BV6
3Fischer et al. Smac Mimetic and NK Cells against Rhabdomyosarcoma
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 202
StemCell Technologies, Canada) according to manufacturer’s 
instructions. The purity of the resulting cell suspension was ana-
lyzed through flow cytometry, using fluorochrome-conjugated 
antibodies against CD56 (clone: HCD56), CD19 (clone: HIB19), 
CD14 (clone: HCD14), CD16 (clone:3G8), CD3 (clone: UCHT1) 
(Biolegend, USA), and CD45 (clone: HI30) (Invitrogen, UK). 
Only cell suspensions that showed more than 85% NK cells were 
taken into culture and used for further experiments. The freshly 
isolated cells were cultured at a concentration of 2 × 106 cells/ml 
of the hematopoietic medium xVivo (Lonzagroup, CH), which 
was enriched with 5% heat-inactivated human plasma, 1% 
PenStrep, 100 U/ml IL-2, and the Smac mimetic BV6 if neces-
sary. The Smac mimetic BV6, which neutralizes XIAP, cIAP1, 
and cIAP2 (34), was kindly provided by Genentech, Inc. (South 
San Francisco, CA, USA). NK cells were fed approximately every 
3 days through discarding half of the medium and adding the 
equivalent amount of fresh medium, containing the doubled 
amount of additives.
Determination of cell Viability and 
Proliferation
To determine at which concentrations SM become toxic to RH30 
and NK cells, the cells were challenged with increasing doses of 
SM, harvested, and stained with 4′,6-diamidino-2-phenylindole 
(DAPI; BioLegend, USA) after 24 and 48 h. The cell suspensions 
were measured by flow cytometry using a BD FACSCanto10c™ 
instrument (BD Bioscience, San Diego, CA, USA) and data were 
analyzed using FlowJo (FlowJo LLC, Ashland, Oregon, USA), first 
gating on single cells, then defining the DAPI negative population 
as viable cells. To analyze the effect of SM on the proliferation 
of NK cells, the cells were isolated and taken into culture as 
described above with increasing doses of SM in addition to IL-2. 
On days 0, 3, 6, and 10, NK cells were harvested and counted 
using the COULTER® Ac·T diff™ Analyzer (Beckman Coulter, 
Germany), an automatic cell counter.
surface Marker Profile analysis
In search of SM-induced alterations in the expression of surface 
markers, unstimulated and SM-stimulated RH30, RD, and NK 
cells were stained with a panel of fluorochrome-conjugated anti-
bodies and analyzed using flow cytometry. NK cells cultured with 
IL-2 alone, as well as cells that were additionally stimulated with 5 
and 10 μM SM were harvested on day 7 of culture, which complies 
with the timepoint of harvest for cytotoxicity assays. First, the 
harvested cells were incubated with 50 μg/ml human IgG (Kiovig, 
Baxter, Germany) in order to saturate the Fc receptors of NK cells 
prior to the staining with fluorochrome-conjugated antibodies. 
This procedure ensured that the antibodies added afterwards 
marked their specific antigen, instead of being captured by 
their Fc fragment through the Fc receptors, which would cause 
a false-positive rate of the particular antigen. Then, a complex 
staining pattern was established including following antibodies: 
CD3/19/14-V450, CD45-BV510 (clone: HI30), CXCR4-PE-Cy7 
(clone: 12G5), DNAX accessory molecule (DNAM)-1-FITC 
(clone: DX11), NKp44-PE (clone: p44-8.1), CD25-PE (clone: 
2A3), CD62L-APC (clone: DREG-56), CD69-BV605 (clone: 
FN50), and CD107a-APC-H7 (clone: H4A3) from BD 
Biosciences, San Diego, CA, USA; CD16-PE-Cy7, CD16-PE, 
and CD253(TRAIL)-PE (clone: RIK-2) from Biolegend, USA; 
NKp30-AlexaFluor488 (clone: 210845), and CCR7-FITC (clone: 
150505) from R&D Systems; KIR2D-FITC (clone: NKVFS1), 
CD158e/k-PE (clone: 5.133), and NKp46-APC (clone: 9E2) from 
Miltenyi, Germany; NKG2A-APC (clone: 1D11) from Beckman 
Coulter, Germany; CX3CR1-PerCPeFluor710 (clone: 2A91) 
from eBiosciences, USA, and DAPI (Biolegend, USA), serving 
as a life–dead stain.
The data were analyzed using FlowJo (FlowJo LLC, Ashland, 
Oregon, USA), analyzing the antigen of interest in the population 
defined as NK cells (DAPI−/CD3−/CD19−/CD45+/CD56+).
For the analysis of the surface marker profile of RH30 and 
RD cells, cells were pretreated according to the conditions used 
as targets in cytotoxicity assays: 0, 5, or 10  μM SM for 24  h. 
Afterwards, these cells were harvested and stained with a stain-
ing panel comprising the following antibodies: MICA (clone: 
AMO1), MICB (clone: BMO2), UL16-binding protein (ULBP)-1 
(clone: AUMO3), -2 (clone: BUMO1), -3 (clone: CUMO3), and 
-4 (clone: 3B6) according to Ref. (35), B7-H6 (kind gift of Prof. 
Adelheid Cerwenka DKFZ, Germany (36)), followed by the 
secondary antibody GAM-APC from Jackson Immunoresearch, 
USA; intercellular adhesion molecule (ICAM)-1-PE (clone: 
HA58), ICAM-2-FITC (clone: CBR-IC2/2), ICAM-3-APC (clone: 
CBR-IC3/1), CD262 (TRAIL-R)-PE, and Nectin-2-PE (clone: 
TX31) from Biolegend, USA; poliovirus receptor (PVR)-FITC 
(clone: 300907) from R&D Systems, as well as DAPI (Biolegend, 
USA). The established data were also analyzed using FlowJo 
(FlowJo LLC, Ashland, Oregon, USA).
cytotoxicity assays
All cytotoxicity assays were performed using a flow cytometry-
based method and an effector to target (E: T) ratio of 10:1. 
Herein, the target cells were stained with carboxyfluorescein 
succinimidyl ester (CFSE; Life Technologies, USA) for 5 minutes 
at room temperature, then washed three times prior to cocul-
ture with unstained effector cells. Coculture was completed in a 
round-bottom 96-well plate for four (pretreated tumor cells) or 
16 h (pretreated NK cells). The RMS target cells were pretreated 
with 5 or 10 μM SM for 3 or 24 h, harvested, and the cell sus-
pension was adjusted to a concentration of 0.25 × 106/ml. The 
NK cells used as effectors were cultured with 100 U/ml IL-2 
alone or with 5 or 10 μM SM in addition to IL-2, harvested on 
day 6 or 7 of culture and the cell suspension was adjusted to a 
concentration of 2.5 × 106/ml. For the analysis of NK cell medi-
ated cytotoxicity, 100 μl of the target and 100 μl of the effector 
cell suspension were pipetted into one well. For each combina-
tion, three wells were filled, representing technical replicates. 
In addition, control wells for all tumor conditions used in the 
experiment were added, containing target cells only in order to 
determine the spontaneous lysis. In the final evaluation of the 
experiment, the specific lysis was calculated as the percentage 
of dead cells in the wells containing target and effector cells 
minus the specific lysis of the respective tumor cell condition. 
Through this calculation of the specific lysis, the percentage of 
killed tumor cells was attributed completely to the NK cells. In 
4Fischer et al. Smac Mimetic and NK Cells against Rhabdomyosarcoma
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addition, three wells were added containing tumor cells and 
ethanol, serving as a positive control for the live-dead stain with 
DAPI. Once the coculture time was over, 100 μl supernatant 
was taken from each well for further analyses (cytometric bead 
assay) and immediately frozen at −80°C. Then, each well was 
harvested using 50  μl Trypsin (Gibco Invitrogen, Germany), 
resuspended in 400 μl of a 1:6,000 DAPI dilution, measured at 
the flow cytometer, and analyzed with FlowJo.
The cytotoxicity assays as described above were repeated 
with different additives, with the aim to elucidate mechanisms 
behind the SM-induced increase in NK cell-mediated killing. 
The role of TNFα was analyzed through the addition of 0.25 mg/
ml Enbrel (Pfizer, Germany); the role of caspases was analyzed 
through the addition of zVAD.fmk (Sigma, Germany) at a 
concentration of 40 μM; and the role of TRAIL was analyzed 
through blocking TRAIL on NK cells with an antibody from 
BD Biosciences, USA (cat. 550515) at a concentration of 50 μg/
ml for 2  hours prior to coculture. The efficiency of the block 
was tested by staining the blocked cells with an antibody of the 
same clone.
Determination of mrna levels of TnFα, 
Trail, relB, iκBα, Trail-r1 (Dr4), and 
Trail-r2 (Dr5)
TRAIL mRNA levels were determined by quantitative real-time 
PCR analysis. Total RNA extraction and cDNA synthesis were 
performed as previously described (37). TRAIL and TNFα 
mRNA levels were assessed by Taqman Gene Expression Assay 
purchased from Life Technologies (TRAIL: Hs00921974_m1; 
TNFα: Hs01113624_g1) and the levels of RelB, IκBα, TRAIL-R1 
(DR4), TRAIL-R2 (DR5), and 28S rRNA by SYBR®Green qPCR 
assay from Applied Biosystems (Darmstadt, Germany) according 
to the manufacturer’s instructions using the 7900HT fast real-time 
PCR system from Applied Biosystems (Darmstadt, Germany); 
RelB forward primer: GCTCTACTTGCTCTGCAGACA; 
reverse primer: GGCCTGGGAGAAGTCAGC; IκBα forward 
primer: GTCAAGGAGCTGCAGGAGAT; reverse primer: ATGG 
CCAAGTGCAGGAAC; DR4 forward primer: GGGTCCACA 
AGACCTTCAAGT; reverse primer: TGCAGCTGAGCTAGGT- 
ACGA; DR5 forward primer: AGACCCTTGTGCTCGTTGTC; 
reverse primer: TTGTTGGGTGATCAGAGCAG; 28S rRNA 
forward primer: TTGAAAATCCGGGGGAGAG; reverse primer: 
ACATTGTTCCAACATGCCAG.
The relative expression of the target gene transcript and refer-
ence gene transcript was calculated as ΔΔCt. 28S rRNA was used 
as reference gene.
cytometric Bead array
In order to screen supernatants of NK and RMS cells in culture 
as well as after coculture in cytotoxicity assays for changes in 
secreted cytokines through treatment with SM, supernatants 
were frozen at −80°C. Cytokine concentrations in these culture 
supernatants were determined by flow cytometry using the 
BD™ CBA Flex Set System (BD Bioscience, San Diego, CA, 
USA). Tests were performed according to the manufacturer’s 
instructions using a mixture of PE-conjugated antibodies against 
the cytokines listed above. Data were acquired with the BD 
FACSVerse™ Bioanalyzer and analysis was carried out by using 
the FCAP Array™ software (v3.0.1).
statistical analysis
Prior to analyses, the Shapiro–Wilk normality test was performed 
in order to prove normal distribution of the analyzed data. The 
statistical analyses of cytotoxicity assays as well as SM-induced 
changes in NK cell surface markers and viability experiments 
were performed using the repeated measures one-way ANOVA 
with Dunnett’s multiple comparison in GraphPad Prism 6 (Inc. 
LA JOLLA, CALIFORNIA, USA). In case of the blocking experi-
ments, which require the comparison of each group with every 
other group rather than the comparison to a control column, 
Turkey’s multiple comparisons test was added to the repeated 
measures one-way ANOVA. Changes in mRNA levels and 
amounts of secreted cytokines upon stimulation with SM were 
analyzed through paired t-tests. All significant differences with a 
p-value less than 0.1 are marked in the results.
resUlTs
nK cells Tolerate higher sM 
concentrations than rMs cells
When testing a substance for its therapeutic potential, such as 
SM for the sensitization of tumor and the stimulation of NK 
cells, a first important piece of information is the optimal dose 
and the concentration of SM that becomes toxic to the respec-
tive cells. In order to investigate this, NK and RMS cells were 
incubated with increasing concentrations of SM and cell viabil-
ity was analyzed after 24 and 48 h using flow cytometry. RH30 
cells already reacted to 10 μM SM with a significantly decreased 
viability after 24 h (IC50 24 h: 15 μM), RD cells showed similar 
results (data not shown). NK cells, however, tolerated doses of 
up to 30 μM (IC50 24 h: 68 μM) (Figures 1A,B). Considering 
the objective of using SM to optimize NK cell therapy, the 
impact of SM on the proliferative behavior of NK cells is also 
of interest. Up to a concentration of 2.5 μM, SM did not affect 
the proliferation of NK cells (Figure 1C). Increasing the dose to 
5 μM SM led to a balance between cell death and proliferation, 
while the presence of 10 μM resulted in a significantly decreased 
cell number (Figure 1C).
Pretreatment of either rMs or nK cells 
with sM increases nK cell-Mediated 
Killing of rMs cells
Following the hypothesis, that SM can restore the defective 
apoptotic machinery in tumor cells and therefore sensitize 
them toward NK cell-mediated killing, cytotoxicity assays were 
performed using targets that were pretreated with SM prior 
to coculture. Indeed, pretreating the ARMS cell line RH30 
cells for 24  h with subtoxic concentrations of SM that had no 
or little effects on cell viability significantly increased the per-
centage of lysed cells from 24 to 54% regarding pretreatment 
with 10  μM SM (Figure  2A). Also, embryonal RD cells were 
rendered more susceptible to NK cell-mediated killing by SM as 
FigUre 1 | natural killer (nK) cells tolerate higher concentrations 
of smac mimetics (sM) than rh30 cells. (a) RH30 and (B) NK cells 
were challenged with increasing doses of SM (0, 2.5, 5, 10, 20, 30, and 
50 μM). The percentage of viable cells was determined with a life–dead 
stain (DAPI) in flow cytometry after 24 and 48 h. (c) NK cells were isolated 
and cultured in medium containing increasing doses of SM in addition to 
IL-2. On day 3, 6, and 9, they were fed with fresh medium including both 
additives and their proliferative behavior was tracked through cell counts. 
The determined cell numbers were considered in relation to the absolute 
number of cells on day 0. Data concerning the impact of SM on RMS cells 
are always depicted in orange (RH30) or red (RD), and NK cells in green 
color. Three individual experiments were performed for each setting 
(n = 3). Statistical analysis with repeated measures one-way 
ANOVA + Dunnett’s multiple comparison, *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001, each referred to 0 μM.
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pretreatment with 10 μM SM increased the specific lysis from 
24 to 45% (Figure S1A in Supplementary Data). To ensure that 
the effectors, IL-2-stimulated NK cells, were responsible for 
the killing, specific lysis was calculated as the difference 
between the percentage of all dead cells (absolute lysis) and the 
percentage of RMS cells that simply died due to pretreatment in 
absence of effectors during the coculture period (spontaneous 
lysis). Furthermore, we observed that a 3-h pretreatment is insuf-
ficient to sensitize RH30 cells toward NK cell-mediated killing 
(Figure S1B in Supplementary Data), similar observations were 
made regarding RD cells (data not shown).
In a next step, we investigated whether SM alter the cytotoxic 
potential of NK cells. For this purpose, cytotoxicity assays were 
performed using NK cells which were stimulated with SM in 
addition to IL-2 during their expansion period as effectors, and 
untreated RH30 cells as targets. The presence of SM during the 
7  days of culture significantly increased the NK cell-mediated 
killing of targets compared to the killing through NK cells 
stimulated with IL-2 alone (Figure  2B). On average, NK cells 
that were stimulated with 10 μM SM in addition to IL-2 killed 
67% of the untreated targets, while IL-2-stimulated NK cells 
only killed 43% (Figure 2B). This SM-stimulated increase in the 
cytotoxic potential of NK cells was seen in every tested donor, 
although the extent of the effect differed. The most impressive 
increase was observed during the experiment with donor four, 
where pretreated cells killed more than twice as much tumor 
cells as the untreated counterpart. We further observed that the 
increase in the cytotoxic potential is limited to the late phase 
killing. Evaluating the same cytotoxicity assays after a coculture 
time of only 4 instead of 16 h did not show comparable results 
(Figure S1C in Supplementary Data). Interestingly, the posi-
tive effect of pretreating NK cells was restricted to the more 
aggressive histological subtype of RMS tested: the ARMS cell 
line RH30. Testing the pretreated NK cells against the untreated 
ERMS cell line RD did not show a comparable result (Figure S1D 
in Supplementary Data).
Trail signaling contributes to sM-
induced sensitization of rMs cells to nK 
cell Killing
Next, we aimed at unveiling the mechanisms that are responsible 
for the SM-conferred sensitization of RMS cells toward NK cell-
mediated killing. Motivated by the hypothesis, that SM induce 
changes within the surface marker profile of RMS cells, untreated 
as well as pretreated cells were stained with fluorochrome-
conjugated antibodies against a broad range of ligands for NK 
cell receptors: ULBP-1, -2, -3, -4, MHC class I polypeptide-related 
sequence (MIC)A, and -B as ligands for natural killer group2, 
member D (NKG2D); ICAM-1, -2, and -3 as ligands for lympho-
cyte function-associated antigen-1; Nectin-2 and PVR as ligands 
for DNAM-1, as well as B7-H6 as a ligand for NKp30. The markers 
were screened for their surface expression and changes in their 
mean fluorescence intensity normalized to the untreated control. 
However, none of the tested surface markers showed a significant 
change in their expression level upon treatment with SM (Figure 
S2 in Supplementary Data). The analyses were performed with 
RH30 (Figure S2A in Supplementary Data) as well as RD cells 
(Figure S2B in Supplementary Data), leading to similar results.
Since SM have been described to stimulate TNFα production, 
which contributes to SM-induced cell death in an autocrine/
paracrine manner (34), we tested whether the increased suscep-
tibility of RH30 cells is dependent on TNFα by adding Enbrel, 
the inhibiting soluble TNF receptor (TNFR2) fused with an IgG1 
Fc part, to the coculture. However, the addition of Enbrel did not 
protect RH30 cells from NK cell-induced killing (Figure  3A), 
FigUre 2 | Pretreatment with sM effects both rh30 and nK cells. (a) SM sensitize RH30 cells toward NK cell mediated killing. RH30 cells were pretreated 
with 0, 5, or 10 μM SM for 24 h prior to being used as targets for IL-2-stimulated NK cells on day six of culture (as depicted in the scheme on the right-hand side). 
The cytotoxicity assay was repeated with NK cells of four different donors (n = 4). E:T ratio = 10:1, coculture time 4 h. (B) SM increase the cytotoxic potential of NK 
cells. NK cells were cultured with different doses of SM (0, 5, and 10 μM) in addition to IL-2 for 7 days (as depicted in the scheme on the right-hand side). On day 
seven, cytotoxicity assays were performed using untreated RH30 cells as targets. The experiment was repeated with NK cells from seven different donors (n = 7). 
E:T ratio = 10:1, coculture time 16 h. Statistical analysis through repeated measures one-way ANOVA + Dunnett’s multiple comparison, ***p < 0.001, 
****p < 0.0001, each referred to 0 μM.
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while Enbrel prevented SM-induced cell death in MDA-MB231 
cells that were used as a positive control, since they have been 
reported to die in a TNFα-dependent manner upon treatment 
with SM (38) (Figure S6A in Supplementary Data). Also, the 
amount of secreted cytokines during the described cytotoxicity 
assays was not altered by pretreatment of RMS with SM (Figure 
S3 in Supplementary Data).
Further, we recently identified TRAIL receptor ligand sign-
aling as another critical mediator of SM-induced cell death 
(38). We therefore asked whether TRAIL is required for the 
SM-mediated sensitization of RH30 cells to NK cell-mediated 
killing. To address this question, we used a TRAIL-blocking 
antibody to neutralize TRAIL on NK cells prior to coculture 
(Figure S6B in Supplementary Data). The presence of the TRAIL-
blocking antibody significantly reduced the SM-conferred sensi-
tization of RH30 cells to NK cell-mediated killing (Figure 3B). 
While neither surface expression of TRAIL-R1 or TRAIL-R2 
on RH30 cells, nor TRAIL expression on NK cells was altered 
by treatment with SM (Figure S4 in Supplementary Data), SM 
significantly increased mRNA levels of the NF-κB target genes 
TRAIL-R1, TRAIL-R2 and TRAIL in RH30 cells (Figure  4). 
SM-stimulated upregulation of TRAIL-R1, TRAIL-R2, and 
TRAIL mRNA expression was confirmed in RD cells (Figure 
S5 in Supplementary Data).
Furthermore, SM have been reported to promote activation 
of caspases by neutralizing XIAP proteins (34), wherefore we 
tested whether caspases are required for the SM-mediated 
sensitization of RH30 cells. To this extent, we added the pan-
caspase inhibitor zVAD.fmk to the medium during cytotoxicity 
assays after functionality of this caspase-blocking inhibitor on 
RH30 cells has been proven in standardized cell death assays 
(Figure S6C in Supplementary Data). Importantly, the presence 
of zVAD.fmk significantly rescued RH30 cells from NK cell-
induced killing (Figure 3C).
FigUre 4 | sM induces upregulation of nF-κB target genes in rh30 cells. Tumor cells pretreated with 10 μM SM for 24 h as well as untreated cells were 
analyzed for mRNA levels of the NF-κB target genes (a) TRAIL-R1, (B) TRAIL-R2, and (c) TRAIL through real time (rt)-PCR. The experiment was repeated with 
RH30 cells from four to six different cell passages, depicted is the fold increase normalized to 0 μM. Statistical analysis through paired t-test, **p < 0.01, +p < 0.1.
FigUre 3 | Defining underlying mechanisms behind the sM-induced sensitization of rh30 cells. Cytotoxicity assays with pretreated RH30 cells as targets 
for IL-2-stimulated natural killer (NK) cells as shown in Figure 2a were performed with the additional presence of (a) Enbrel, a TNFα blocker (concentration 250 μg/
ml) or (c) zVAD.fmk (concentration 40 μM) during coculture. In panel (B), TRAIL on NK cells was blocked through incubation with an antibody (concentration 50 μg/
ml) prior to coculture. Each experiment was repeated with NK cells from three different donors (n = 3), E:T ratio = 10:1, coculture 4 h. Statistical analysis with 
repeated measures one-way ANOVA with Turkey’s multiple comparison, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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TnFα signaling contributes to sM-
induced increase in the cytotoxic 
Potential of nK cells against rh30 cells
To elucidate which mechanisms are responsible for the 
SM-induced increase in the cytotoxic potential of NK cells, we 
first screened a broad range of NK cell surface molecules for 
changes upon treatment with SM: activating NK cell receptors 
(NKp30, NKp44, NKp46, NKG2D, DNAM-1, and CD16) (Figure 
S7A in Supplementary Data), chemokine receptors (CCR7, 
CX3CR1, and CXCR4) (Figure S7B in Supplementary Data), 
inhibitory NK cell receptors (NKG2A and KIR2D) (Figure S7C 
in Supplementary Data), and activation markers (CD25, CD107a, 
CD69, CD62L) (Figure S7D in Supplementary Data). Generally 
speaking, we observed a donor-dependent influence of SM on 
the expression of NK cell surface proteins. Only two of the tested 
molecules showed a consistent, donor-independent change: 
CX3CR1, a chemokine receptor, was upregulated, while NKp46 
was downregulated upon treatment with SM.
In further search of underlying mechanisms, we investigated 
the role of TNFα during cytotoxicity assays with SM-pretreated 
NK cells against RH30 cells by adding Enbrel to the medium 
during coculture. In fact, the SM-induced increase in NK 
cell-mediated killing was reduced by the presence of Enbrel 
(Figure 5A). Although this protection by Enbrel was partial, it was 
consistently found in each of the four tested donors (Figure 5A). 
Correspondingly, we detected a significant increase in secreted 
TNFα in supernatants of SM-pretreated compared to untreated 
NK cells at the end of the coculture period of the cytotoxicity 
assays. Besides TNFα, the levels of IFN-γ were significantly 
increased in these supernatants (Figure  5B), while IFN-α and 
FasL levels remained unchanged (data not shown). Interestingly, 
we could only observe this increase in TNFα and IFN-γ levels 
when the untreated and SM-pretreated NK cells were challenged 
with their target cells and not upon SM-induction alone (Figure 
S8 in Supplementary Data).
There are probably further mechanisms contributing to the 
increased level of activation of NK cells. In line with our findings 
FigUre 5 | Defining mechanisms behind the sM-mediated stimulation of nK cells. (a) Cytotoxicity assays with pretreated NK cells (SM in addition to IL-2 
for 7 days) against untreated RH30 cells (as shown in Figure 2B) were repeated under the presence of Enbrel, a TNFα blocker (concentration 250 μg/ml). The 
experiment was performed with NK cells of four different donors (n = 4), E:T ratio = 10:1, coculture time 16 h. Statistical analysis through repeated measures 
one-way ANOVA were not significant. (B) At the end of coculture of the experiments described under (a), supernatants were taken away and analyzed using 
cytometric bead array. The graph shows the fold increase in the amount of TNFα and IFN-γ normalized to 0 μM. The experiment was repeated from three different 
cytotoxicity assays (n = 3). Statistical analysis through paired t-test, +p < 0.1, ***p < 0.001.
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in tumor cells, we detected an increase in RelB and IκBα mRNA 
levels, also indicating an activation of NF-κB signaling in 
SM-treated NK cells. Also, the NF-κB target gene TRAIL was 
found to be upregulated, while mRNA levels of TNFα were 
lower than in the untreated control (Figure 6).
DiscUssiOn
Since immune effector cells including NK cells mainly function 
by inducing apoptosis in their targets, the efficacy of immuno-
therapy critically depends on intact apoptosis signaling pathways 
within the targeted cancer cells. Here, we report that SM, which 
antagonize IAP proteins, can prime RMS cells toward NK cell-
mediated cytotoxicity (as shown for RD and RH30 cells), and 
increase the cytotoxic potential of NK cells toward RH30 cells. Of 
note, the simultaneous targeting of tumor and immune cells with 
one single drug was restricted to the more aggressive alveolar 
RH30 cell line.
Importantly, we found that TRAIL signaling contributes to 
SM-induced sensitization of RMS cells toward NK cell-mediated 
cytotoxicity, as the addition of a neutralizing TRAIL antibody 
on NK cells prior to coculture with tumor cells significantly 
reduced tumor lysis. While we confirmed the overall expression 
of TRAIL on IL-2-stimulated NK cells, as well as the upregulation 
of the NF-κB target gene TRAIL in RMS cells upon treatment 
with SM, we did not detect any changes in neither TRAIL-R1 or 
TRAIL-R2 expression on RMS cells, nor TRAIL expression on 
NK cells upon exposure to SM. Overall, our findings are consist-
ent with our previous reports showing that SM or Smac peptides 
can prime cancer cells toward TRAIL in  vitro and in  vivo (39, 
40). In addition, we recently identified TRAIL receptor ligand 
signaling as one critical mediator of SM-induced cell death (38). 
Also, cooperative TRAIL production has been shown to mediate 
SM/IFNα-induced cell death in TNFα-resistant solid cancer cells 
(41). By comparison, TRAIL signaling turned out to be dispen-
sable for SM/glucocorticoid-induced cell death in leukemia cells 
(42) or in SM/temozolomide-triggered cell death in glioblastoma 
cells (43). This indicates that the TRAIL system contributes to 
SM-induced cell death in a context-dependent manner.
Interestingly, we found a differential role of TNFα in 
SM-imposed sensitization of RMS cells to NK cell killing, 
depending on whether RMS or NK cells were pretreated with 
SM. TNFα contributes, at least to some extent, to the enhanced 
cytotoxicity when NK cells were pretreated with SM, since the 
addition of TNFα-blocking Enbrel to the medium during the 
killing assay significantly, although partially, decreased the NK 
cell-mediated killing of RH30 cells. In addition, SM-pretreated 
NK cells produce significantly higher amounts of TNFα and 
IFN-γ than their untreated counterpart, when cocultured with 
their tumor target cells. However, beside the possible relevance 
of TNFα, there are likely additional mechanisms contributing to 
the SM-induced activation of NK cells, for example, activation of 
NF-κB signaling through SM.
On the contrary, TNFα was found to be dispensable for the 
enhanced cytotoxicity of NK cells when RMS cells were pretreated 
with SM, since the addition of Enbrel to cytotoxicity assays failed 
to rescue RMS cells from NK cell-mediated killing. This is under-
lined by the fact that the supernatants of pretreated RMS cells did 
not contain more TNFα than the untreated cells. These findings 
are consistent with previous studies on a context-dependent 
impact of TNFα as a mediator of SM-induced cytotoxicity. On 
the one hand, there are several studies showing that an autocrine/
paracrine TNFα loop plays a critical role in SM-induced cell death 
(34, 44–48). On the other hand, blockage of TNFα signaling has 
also been reported to fail in providing protection against SM 
in other settings (38, 42, 43). We previously demonstrated that 
FigUre 6 | sM induces upregulation of nF-κB target genes in natural killer (nK) cells. NK cells cultured for 7 days with IL-2 alone and in addition with SM 
were analyzed for mRNA levels of the NF-κB target genes (a) RelB, (B) IκBα, (c) TRAIL, and (D) TNFα through rt-PCR. The experiment was repeated with NK cells 
from three to six different donors, depicted is the fold increase normalized to 0 μM. Statistical analysis through paired t-test, *p < 0.05, ***p < 0.001.
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cell type-dependent sensitivity to TNFα can determine whether 
a cell line depends on TNFα signaling to mediate BV6-induced 
cell death (41). In TNFα-resistant types of cancer, we showed that 
TRAIL as another death receptor ligand can mediate SM-induced 
cell death instead of TNFα (41). Also, differential upregulation of 
TNFα upon SM might explain TNFα dependency in some but 
not other instances.
While the monovalent SM LCL161 has previously been 
reported to upregulate ligands for the activating NK cell recep-
tor NKG2D such as MICA and MICB (49), we did not detect 
changes in NK cell receptor ligands on RMS cells upon treatment 
with the SM BV6, which might be due to different tumor types 
or different SM.
Moreover, caspase-dependent as well as caspase-independent 
effector pathways may be involved in the SM-conferred increased 
sensitivity of RH30 cells toward NK cell killing. Our finding 
that the presence of zVAD.fmk, a pancaspase inhibitor, rescues 
tumor cells from the increase in killing indicates an apoptosis-
dependent cell death in line with previous reports that zVAD.
fmk rescues tumor cells from increased cytotoxicity of NK or 
cytokine-induced killer cells (50, 51).
It is also interesting to note that a 24-h pretreatment with 
BV6 was necessary to adequately sensitize RMS cells to NK cell 
cytotoxicity, while a pretreatment of only three hours turned 
out to be insufficient. By comparison, we previously reported 
that a 4-h pretreatment with BV6 primed RMS cells for CIK 
cell-mediated killing (50). One possible explanation for the dif-
ferent requirement of preincubation time is a difference in the 
cytotoxicity of NK versus CIK cells. Alternatively, these findings 
may indicate that neither the depletion of cIAPs, nor the direct 
release of caspases from XIAP proteins, which has been reported 
to occur within minutes or hours upon exposure to BV6 (34), 
are responsible for the BV6-conferred sensitization of RMS cells 
to NK cell-mediated killing. Rather, induction and subsequent 
expression of proteins or cytokines, for example, as the result of 
SM-stimulated engagement of alternative NF-κB signaling upon 
cIAP1/2 depletion, might be necessary which requires some 
time. Consistently, we found upregulation of several NF-κB 
target genes, including proapoptotic genes such as TRAIL-R1, 
TRAIL-R2, and TRAIL, in SM-treated RMS cells.
On the NK cell side, the expression of killer immunoglobulin 
like receptors (KIRs) was slightly decreased as detected by an 
antibody recognizing the common extracellular Ig-like domains 
of the KIR2D receptor family—a family whose greater part 
belongs to the inhibitory receptors. Therefore, the decrease 
observed might minimize the inhibitory signals within the 
NK cell and lower the threshold for NK cell activation. This 
in addition to the increase of CX3CR1 might contribute to 
the activating effect, even though it is difficult to envisage 
one of these molecules operating as a key player. In contrast, 
NKp46, another activating receptor, shows a clear tendency to 
be downregulated upon exposure to SM, possibly lowering the 
state of activation in NK cells. All in all, as the increase of 
the cytotoxic potential through stimulation with SM observed 
during the cytotoxicity assays was clearly donor-independent, 
we conclude that the activating effect of SM on NK cell function 
is not absolutely attributable to changes in the expression of 
surface molecules.
Consistent with our findings demonstrating that SM at 
non-toxic concentrations enhance NK cell cytotoxicity, there 
is increasing evidence showing that SM can potentiate cancer 
immunotherapy not only by promoting apoptosis of cancer cells 
but also by modulating immune cell functions without induc-
ing cell death in the majority of immune cells. For example, SM 
have been shown to augment human and mouse T-cell responses 
to physiologically relevant stimuli via activation of alternative 
NF-κB signaling (52). In addition, SM were described to increase 
in vitro expansion of antigen-specific naive and memory T cells 
to enhance T-lymphocyte function (53), to trigger phenotypic 
maturation of monocyte-derived dendritic cells (DCs) (53), and 
to stimulate maturation of immature DCs (54).
Taken together, SM represent an interesting strategy in opti-
mizing NK cell therapy for the treatment of RMS by sensitizing 
the tumor cells to NK cell-mediated cell death on the one hand, 
and by directly activating NK cells on the other (Figure 7).
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